NASDAQ: SMMT
Summit Therapeutics Inc Stock Ownership - Who owns Summit Therapeutics?

Insider buying vs selling

Have Summit Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Robert W. DugganCo-Chief Executive Officer2026-06-123,810,000$13.12
$49.99MBuy
Mahkam ZanganehCo-Chief Executive Officer2026-06-123,810,000$13.12
$49.99MBuy
Manmeet Singh SoniCOO and CFO2026-06-0425,000$14.46
$361.50kBuy
Robert W. DugganCo-Chief Executive Officer2026-06-04100,000$14.60
$1.46MBuy
Manmeet Singh SoniCOO and CFO2026-06-0425,000$14.43
$360.75kBuy
Mahkam ZanganehCo-Chief Executive Officer2026-06-04100,000$14.60
$1.46MBuy
Mahkam ZanganehCo-Chief Executive Officer2025-10-2113,980,789$18.74
$262.00MBuy
Mahkam ZanganehCo-Chief Executive Officer2025-10-2126,680$18.74
$499.98kBuy
Robert W. DugganCo-Chief Executive Officer2025-10-2113,980,789$18.74
$262.00MBuy
Robert W. DugganCo-Chief Executive Officer2025-10-21266,808$18.74
$5.00MBuy

1 of 2

SMMT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SMMT insiders and whales buy or sell their stock.

SMMT Shareholders

What type of owners hold Summit Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Mahkam Zanganeh80.79%644,473,702$8.45BInsider
Robert W. Duggan76.47%610,015,809$8.00BInsider
Yu Xia4.02%32,057,147$420.27MInsider
Maky Zanganeh1.87%14,915,775$195.55MInsider
Manmeet Singh Soni0.39%3,123,603$40.95MInsider
Ankur Dhingra0.05%394,485$5.17MInsider
Bhaskar Anand0.02%159,751$2.09MInsider
Jeff Huber0.01%56,052$734.84kInsider
Baker Bros Advisors LP0.00%32,786$429.82kInstitution
Bakbro0.00%32,786$429.82kInstitution

1 of 3

SMMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SMMT0.01%99.99%Net BuyingNet Buying
KRYS0.10%24.37%Net SellingNet Selling
IONS0.11%3.34%Net SellingNet Selling
PTGX0.12%22.54%Net SellingNet Buying
KYMR0.12%31.95%Net SellingNet Selling

Summit Therapeutics Stock Ownership FAQ

Who owns Summit Therapeutics?

Summit Therapeutics (NASDAQ: SMMT) is owned by 0.02% institutional shareholders, 163.61% Summit Therapeutics insiders, and 0.00% retail investors. Mahkam Zanganeh is the largest individual Summit Therapeutics shareholder, owning 644.47M shares representing 80.79% of the company. Mahkam Zanganeh's Summit Therapeutics shares are currently valued at $8.01B.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.